Tumour vasculature targeting agents in hybrid/conjugate drugs.

Tumour vasculature targeting agents in hybrid/conjugate drugs.

Item
http://www.wikidata.org/entity/Q38094627
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisAnti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer.A new target ligand Ser-Glu for PEPT1-overexpressing cancer imagingTRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions.An overview of molecular hybrids in drug discovery.Wogonoside inhibits angiogenesis in breast cancer via suppressing Wnt/β-catenin pathway.18F-Radiolabeling, preliminary evaluation of folate-pHPMA conjugates via PET.Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines.Flow-Responsive Vascular Endothelial Growth Factor Receptor-Protein Kinase C Isoform Epsilon Signaling Mediates Glycolytic Metabolites for Vascular Repair.
P2860

Tumour vasculature targeting agents in hybrid/conjugate drugs.

Item
http://www.wikidata.org/entity/Q38094627
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tumour vasculature targeting agents in hybrid/conjugate drugs.
@en
type
label
Tumour vasculature targeting agents in hybrid/conjugate drugs.
@en
prefLabel
Tumour vasculature targeting agents in hybrid/conjugate drugs.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Tumour vasculature targeting agents in hybrid/conjugate drugs.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698